Targeting UICLM for Colorectal Cancer Treatment (G200772)

Target Name: UICLM

NCBI ID: G200772

UICLM

Other Name(s): Up-regulated in colorectal cancer liver metastasis | CROCC2-AS1 | up-regulated in colorectal cancer liver metastasis

Targeting UICLM for Colorectal Cancer Treatment

UICLM, or Up-regulated in colorectal cancer liver metastasis, is a protein that has been identified as a potential drug target or biomarker in colorectal cancer. It is a highly upregulated gene in the liver of patients with colorectal cancer, which means that its expression level is higher than in other tissues.

The liver is a crucial organ for the detoxification and processing of many harmful substances, including cancer cells. Therefore, any drug that can effectively target UICLM in the liver has the potential to be highly effective in treating colorectal cancer.

One of the main advantages of targeting UICLM is its location in the liver. The liver is a large and complex organ, but it is also a key site for the majority of drug-resistant cancer cells. By targeting UICLM in the liver, a drug can directly target these cells and minimize the risk of unintended side effects in other parts of the body.

Another potential advantage of targeting UICLM is its role in the development and progression of colorectal cancer. UICLM has been shown to be highly upregulated in the liver of patients with colorectal cancer, which suggests that it may be a key factor in the development of these deadly diseases. By targeting UICLM, a drug may be able to inhibit its role in the growth and progression of cancer cells, leading to a potential treatment for colorectal cancer.

In addition to its potential as a drug target, UICLM is also a potential biomarker for colorectal cancer. The liver is a key site for the production of many proteins, including those that are involved in cell signaling and growth. Therefore, changes in the levels of these proteins in the liver may be an important indicator of the presence and progression of colorectal cancer.

Research has shown that UICLM is highly upregulated in the liver of patients with colorectal cancer. This suggests that targeting this protein may be a promising strategy for the treatment of colorectal cancer. By inhibiting the role of UICLM in the growth and progression of cancer cells, a drug may be able to effectively treat this deadly disease.

Targeting UICLM in the liver is still a relatively new concept, and much more research is needed to fully understand its role in colorectal cancer. However, based on the promising results from early studies, it is clear that UICLM is a protein that has the potential to be a valuable drug target or biomarker in the treatment of colorectal cancer.

Protein Name: Up-regulated In Colorectal Cancer Liver Metastasis

The "UICLM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UICLM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets